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From the Institut für Klinische Chemie, Deutsches Herzzentrum München ; Vorstand: Prof. Dr . H . Schievelbein 
Toxicological and Clinical Aspects of Cyanide Metabolism 
By R. G. H . Baumeister 1), Η . Schievelbein and G. Zickgraf-Rüdel 
Summary: This contribution deals with the occurrence of 
cyanide and its biological pathways in the body. Especially 
possibilities of detoxification are pointed out. 
Intoxications are caused by acute and chronical cyanide 
uptake. Tobacco amblyopia, retrobulbar neuritis in perni-
cious anaemia, Leber's optic atrophy, Nigerian nutritional 
neuropathy, and sterility in female heavy smokers are at-
tributed to cyanide intoxication. 
Various methods for treating acute and chronic cyanide 
intoxication are discussed. 
Zusammenfassung: Toxikologische und klinische Aspekte 
der Metabolisierung von Cyanid 
Das Vorkommen von Cyanid und sein Stoffwechsel im Kör-
per werden beschrieben. Auf die bestehenden Entgiftungs-
möglichkeiten wird besonders verwiesen. 
Vergiftungen können bei einmaliger und chronischer Cya-
nidaufnähme entstehen. Die Tabakamblyopie, die Retro-
bulbärneuritis bei perniziöser Anämie, die Lebersche Opti-
kusatrophie, die nigerianische ernährungsbedingte atakti-
sche Neuropathie sowie die Sterilität bei starken Rauche-
rinnen werden auf eine chronische Cyanidv er giftung zurück-
geführt. 
Auf die Behandlung der akuten und der chronischen Cya-
nidvergiftung wird eingegangen. 
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1. Introduction 
In recent years it has been possible to establish a connection 
between the pathogenesis of several diseases and the impair-
!) Chirurgische Universitätsklinik München (FRG). 
ed metabolism of cyanide. Successful therapeutic measures 
confirm these assumed relations, which partially could al­
ready be proved experimentally. Moreover certain connec­
tions between the metabolism of vitamin B 1 2 and cyanide 
poisoning were detected. 
For these reasons it seems worthwhile to review the know­
ledge on the metabolism of cyanide, taking into considera­
tion the occurrence and mechanism of detoxication of cya­
nide. 
2. Occurrence of cyanide 
Traces of cyanide can be demonstrated in almost all plants. 
According to Montgomery (1969) i t is found mainly in form 
of cyanogenic glycosides. Cyanogenic glycosides are com­
pounds from which one or more sugar molecules and an 
aldehyde or ketone are liberated by treatment with acid 
(Conn 1969). Table 1 shows a compilation of plants wi th 
extremely high cyanide content. Furthermore it is known 
that the pips of several berries and the stones of several 
prunus species (e.g. almond, cherry, apricot) contain con­
siderable amounts of cyanogenic glycosides in several instan­
ces (Moeschlin 1964). Also by intake of several sorts of cab­
bage amounts of cyanogenic glycosides, which are not acutely 
toxic, can be ingested (Werle 1969). Besides the wide-spread 
occurrence in plants (Dilleman 1959) cyanogenic glycosides 
are also found in insects (Blum and Woodring 1962; Eisner 
et al. 1963; Jones et al. 1962; Schildknecht et al. 1968; Blum 
1056 Arzneim.-Forsch. (Drug Res.) 25, Nr. 7 (1975) Baumeister et al. - Cyanide 
Table 1: Cyanide content of various nutritional plants according to 
Montgomery (1969) and Pulss (1967). 
Plant 
HCN 
content 
(mg/100 g) 
Literature 
Bitter almond 250 Poison and Tattersall (1969) 
Bitter cassava 
bark of root/dried 
stem 
root (total) 
245 
113 
55—90 
Collens (1915) 
Collens (1915) 
Clark (1936) 
Sorghum 
fresh leaves 0—15 Stählin (1957) 
Bamboo 
tops of unripe sprouts 
stem, unripe 
800 
300 
Baggchi and Ganguli 
(1943) 
Baggchi and Ganguli 
(1943) 
Lima bean 
(Phaseolus lunatus) 
several variations 
Java, coloured 
Puerto Rico, black 
Burma, white 
Arizona, coloured 
America, white 
312 
300 
300 
17 
10 
Guignard (1907) 
Viehocver (1940) 
Kohn-Abrcst (1906) 
Montgomery (1964) 
Montgomery (1964) 
Linseed products 30—50 Lüdtke (1952); Pulss (1962) 
White clover 20—30 Corkill (1940); 
Melville et al. (1940); 
Pulss (1962) 
et al. 1962; Barbetta 1966; Guldensteeden-Egeling 1882; 
Wheeler 1890) and in fungi (Tschiersch 1967). 
As to the occurrence of H C N in insects, i t could be demon­
strated in the secretion of the defense gland of two groups 
of millepedes. Pachymerium ferrugineum belonging to the 
chilopodes contains about 2.2 ng H C N per animal (Schild­
knecht et al. J968). H C N from mandelonitril (Blum et al. 
1962; Barbetta 1966) was also demonstrated in polydes-
moidea, a millipede belonging to the diplopodes (Gulden­
steeden-Egeling 1882; Wheeler 1890). 
I n tobacco smoke, cyanide occurs in considerable amounts, 
the concentration of which differs from one sort of tobacco 
to the next (Osborne 1956; Wynder l967 ; Elmenhorst 1968; 
Stedman 1968). I n the main stream of tobacco smoke of 
cigarettes without filter Ar tho and Koch found values be­
tween 150 and 300 //g, which were in the range of the data 
obtained by other authors (Newsome et al. 1965). Also the 
order of magnitude of our own data corresponds wi th these 
results (Baumeister and Schievelbein 1971). 
I n cigarettes wi th cellulose acetate filter only a negligible 
retention by the filter was observed. Suitable absorbent 
filters on the other hand reduce the original cyanide content 
by 20 to 80%. The cyanide content of the particle phase per 
cigarette amounts to approximately 100 («g CN"/cigarette 
as well in Blend cigarettes as in Maryland cigarettes. The 
cyanide values in the gaseous phase are slightly higher. For 
Blend cigarettes they amount to about 150 fig CN~/cigar-
ette, for Maryland cigarettes about 120 ug CN'/cigarette 
(Artho and Koch 1969) 2). 
Inhalation of H C N compounds in the chemical and galvanic 
industry as well as during gold extraction is another possib­
i l i ty for humans to take up considerable amounts of cyanide. 
The poisoning that means the liberation of H C N from organic 
thiocyanates (plant protective agents) is of importance. I t 
is accomplished in insects and mammals by the enzyme 
2 ) Blend cigarettes containing a tobacco mixture while Maryland 
cigarettes are made of Virginia tobacco exclusively. 
glutathione-S-transferase, mainly from lower aliphatic 
homologues. This fact explains the high toxicity of some 
lower alkyl derivatives of thiocyanate (Gleason et al. 1969). 
Also liberation of cyanide from succinonitrile has been 
described recently (Contessa and Santi 1973). 
3. Metabolic pathways of cyanide in the organism 
H C N may get into the organism via the lungs, the gastro­
intestinal tract and also via the skin. I f H C N is taken up 
orally amounts of 0.5 mg to 3.5 mg/kg body weight may 
already be fatal for humans (Chen et al. 1934; Gettler and 
Baine 1938; Halstrom and Moller 1945). 
The maximum concentration at the working place ( M A K 
maximale Arbeitsplatz-Konzentration) permitted for H C N 
is 10 ppm in the Federal Republic of Germany (1 ppm = 
part per mil l ion = 1 wg/llter). 100 ppm are dangerous to 
life, 270 ppm are fatal within a short time. The toxic effect 
of H C N is caused by its high affinity to cytochrome oxidase. 
Inspite of reversible binding to this enzyme H C N causes an 
immediate inhibition of cellular respiration. 
Several ways of metabolism were described, by which 
cyanide may be detoxified. These ways can be demonstrated 
in the living organism by administration of radioactive-
labelled cyanide compounds. 
Following injection of N a 1 4 C N in dogs 1 4 C appears in urine 
in free cyanide as a constituent of cyanocobalamine and in 
thiocyanate. A great part of the cyanide and thiocyanate 
carbon is oxidized directly to form C 0 2 , which is achieved, 
according to Boxer and Rickards (1952), probably via 
cyan ate. 
The carbon of cyanide and probably as a result of metabolic 
balance also the carbon of thiocyanate appears in the carbon 
of the methyl group of choline and methionine and in the 
urea-C of allantoine as well . The formic acid isolated in 
these experiments contains a high amount of 1 4 C. Based on 
this fact formic acid could be considered as starting material 
for the introduction of the cyanide carbon into the one-
carbon-metabolism (Boxer and Rickards 1952). 
After subcutaneous injection of sodium cyanide in rats 2-
imino-4-thiazolidine-carboxylic acid could be isolated from 
urine (Wood and Cooley 1956). In this case cyanide is 
thought to react wi th cystine forming cysteine and /?-thio-
cyanoalanine. 
The latter is tautomerized forming 2-amino-thiazolidine-4-
carboxylic acid or the equivalent 2-imino-4-thiazolidine-
carboxylic acid (Schöbeii et al. 1951). The second compound 
proved to be metabolic-inert in rats (Wood and Cooley 
1956). 
The detoxification of cyanide compounds forming thio­
cyanate can be achieved on two metabolic pathways. One 
reaction which has already been known for a longer time is 
catalysed by the enzyme thiosulphate-sulphurtransferase 
(EC 2.8.1.1) named rhodanese by Lang (1933). Thiosulphate 
and cyanide form thiocyanate and sulphite in this reaction. 
I n the second way 3-mercaptopyruvate, which can be formed 
by transaminidation of L-cysteine, acts as sulphur-donator. 
Thiocyanate and pyruvate are formed at the cyanide-sul-
phurtransferase (EC 2.8.1.2) (Fiedler and Wodd 1956). I n 
Scheme 1 the above described pathways of cyanide meta­
bolism are shown. 
The different pathways of metabolism are utilized to various 
de grees in the organism. Balance investigations which could 
give an insight into the utilization of the different pathways 
have not been published. But i t can be assumed that the 
detoxification to thiocyanate accounts for the main part. 
After injection of sodium cyanide in rat 80% of the inject­
ed cyanide was found in urine as thiocyanate (Wood and 
Cooley 1956). The therapeutic effect of thiosulphate in 
cyanide intoxication, also combined wi th rhodanese (Cle-
medson et al. 1954), could as well be a hint that the detoxi­
fication of cyanide by means of thiosulphate-sulphurtrans-
ferase is of great importance. 
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CN- Η- S.O» 
CN- + 
thiosulphate-
sulphurlransferase 
3-mercapto cyanide 
— SOr - + SCN 
pyruvate 1 SCN 
pyruvate sulphurtransferasc 
CN~ -h hydroxocobalaminc cyanocobalamine 
CN- + cystine 2-amino-thiazolodine-4-carboxylic acid -f cystein 
(2-imino-4-thiazolodine-carboxylic acid) 
1-C-mctabolism CN- formic acid 
incorporation of cyanide-carbon into choline, methionine, allantoinc 
oxidation to CO. 
elimination via lungs and kidneys 
inhibition of cytochrome oxydase 
Scheme 1: Pathways of cyanide metabolism in the organism. 
3.1. Thiocyanate 
Since the first description of the occurrence of thiocyanate 
in saliva by Treviranus (1814) and since the detection of 
HCN(hydrocyanic acid)-detoxification by means of rhod-
anid formation by Lang (1895), a number of investigations 
on relations between the concentration of this metabolite and 
its physiologic and pathologic states have been published. 
Of special interest are the changes wi th in cyanide metabolism 
under the influence of smoking, which is probably the most 
common way of cyanide intake. For the first time Claude 
Bernard observed that smokers excreted considerably higher 
amounts of thiocyanate than did non-smokers (after Pick 
1910). This observation was confirmed by many authors, 
recently by Stoa (1951) and Maliszewsky and Bass (1955). 
Table 2 shows the thiocyanate concentration i n blood and 
saliva and the excretion in urine of smokers and non-
smokers. 
Table 2: SCN- concentration in blood, saliva, and urine of smokers 
and non-smokers. Range and mean value according to Larson (1961). 
Non-smokers Smokers 
Blood (serum) 0.025—1.21 m - 0.379 0.06 --2.48 m = 1.06 
(mg/100 ml) 8 authors 
Saliva 2.03 —26.5 m - 5.54 7.57 --27.5 m - 12.82 
(mg/100 ml) 3 authors 
Urine 0.002—0.232 m ---- 0.117 0.012--0.283 m = 0.147 
(g/24 h) 2 authors 
Compared wi th non-smokers the thiocyanate content in 
blood and serum of smokers was raised by 100—300% 
according to Schreiber (1925), B lum (1928), Lawton et al. 
(1943), Trasoff and Schneeberg (1944), Ramos and Visca 
(1945), Stoa (1951), Maliszewsky and Bass (1955). On the 
other hand, Caviness (1948) did not find a statistically sig­
nificant difference between smokers and non-smokers. 
The question concerning a direct correlation between con­
sumption of cigarettes and the thiocyanate content in blood 
was answered by some authors positive (Schreiber 1925) and 
by others negative (Lawton et al. 1943). Also no agreement 
exists about the content of thiocyanate in saliva. Both ele­
vation and lowering of thiocyanate content have been de­
scribed (Mendel and Schneider 1900; Fleckscher 1905; Cul-
verwell 1915; Eschler et al. 1968; Barylko-Pikielna and 
Pangborn 1968). On the other hand, agreement exists that 
more thiocyanate is excreted in urine of smokers than of 
non-smokers (Pick 1910; Lawton et al. 1934; Maliszewsky 
and Bass 1955; Wokes 1958). 
The fol lowing separate results shall be mentioned: the thio­
cyanate content in the higher cerebrospinal fluid parallels 
the content in serum (Blum 1928). I n two smokers the thio­
cyanate content of sweat was considerably higher than in 
non-smokers (Maliszewsky and Bass 1955). Patients wi th 
subacute combined degeneration who smoked had signifi­
cantly lowered plasma thiocyanate levels than control smo­
kers, but plasma thiocyanate levels in non-smoking patients 
wi th neurological disease due to vi tamin B , 2 deficiency were 
not statistically different from control values (Wells et al. 
1972). 
The uptake of higher amounts of thiocyanate causes patho­
logical states in humans. Development of a struma by iodine 
deficiency wi th all symptoms of hyperthyreosis is a known 
sequence (Moeschlin 1964). Inhibi t ion of the active iodine 
transport and consequently of the iodine uptake into 
thyroid gland is the cause for this effect. Barnell and cowor­
kers (1957) reported on frequent occurrence of a thio­
cyanate psychosis during treatment of hypertension wi th 
thiocyanate. 
3.2. Thiosulphate-sulphurtransferase 
The formation of thiocyanate by an enzymatic reaction was 
described in 1933 by K . Lang. He proposed the name 
"rhodanese" for the respective enzyme. The systemic name 
is now: thiosulphate-cyanide-sulphurtransferase (EC 2.8.1.1) 
or thiosulphate-sulphurtransferase. 
Lang found this enzyme in almost every organ of man, 
frog, rabbit, cattle, chicken, pigeon, cat, and dog, but neither 
in blood nor in muscle. Contrary to these findings, Himwich 
and Sanders (1948) could demonstrate this enzyme in the 
blood of dogs and in musyle of dogs and Rhesus monkeys. 
Also Reinwein (1961) found thiosulphate-sulphurtransferase 
in all organs of man, horse, pig, sheep, cattle, and rat, but 
not in serum. There is no correlation between the activity 
of this enzyme and the concentration of thiocyanate within 
the organs 3). Regarding the intracellular distribution of this 
enzvme it is mainly found in the mitochondria (Sörbo 
1951 a,b). 
The total capacity of detoxification was approximately 
calculated by Himwich and Sanders (1948). The liver of 
a dog should be able to detoxicate 4.015 g cyanide within 15 
min, the total skeletal muscle apparatus 1.763 g within the 
same time. This calculation is not met by the poor tolerance 
of the animal organism against cyanide. The authors, there­
fore, conclude that the l imi t ing factor for detoxication of 
cyanide is the availability of the thiosulphate-sulphurtrans-
ferase. Possibly also a deficiency of sulphur donators may 
play a part, since a threefold higher concentration of thio­
sulphate compared wi th the cyanide, which is to be 
detoxicated, is necessary in vitro, to form thiocyanate in 
sufficient amounts. 
A n additional reaction, catalysed by rhodanese is described 
by Villarejo and Westley (1963). The enzyme is supposed 
also to mediate the reduction of thiosulphate to sulphite 
and sulphide, which is concluded from investigations with 
crystallized rhodanese from bovine liver. As reducing agents 
liponal and liponamide are used. Also the counterreaction 
was described. 
3.3. Cyano- and hydroxocobalaminc 
I n this survey mainly the cyanide compound of cobalamine 
is of interest, which seems to be important in certain patho­
logical states. 
As shown in Scheme 1 vitamin B 1 2 shares in the detoxi­
cation of cyanide. Two forms of the vitamin have been 
known for a long time. Depending on the connection of the 
central cobalt atom with a hydroxyl or a cyanide group 
(Brink et al. 1950), one has to deal with hydroxo- or aquo-
cobalamine and with cyanocobalamine. When solutions of 
cyanocobalamine are exposed to light the coordinatively 
bound cyanide is split off. On the other hand, in neutral 
solutions hydroxocobalamine can react wi th excess K C N to 
form cyanocobalamine. 
In addition to the coordinatively bound cyanide, cyano­
cobalamine can react with two other moles cyanide to form 
3 ) Thiosulphate-sulphur-transferase and thiocyanate were also 
found in bacteria, protozoa, helminthes, mollusca and echino-
dermata (Schievelbein and Baumeister 1969; Schievelbein et al. 
1969; Baumeister 1972). 
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complexes (Beavan 1950; Conn et al. 1951; Conn and Wart-
mann 1952). 
There are several investigations regarding changes of the Bl2 
metabolism in smokers and non-smokers. These are import­
ant for the understanding of the pathogenesis of tobacco 
amblyopia. 
A comparative study (Linnel et al. 1968) on the serum B 1 2 
level, the excretion of vitamin B 1 2 in the urine and the 
excretion of thiocyanate in the urine as parameters for the 
detoxification of cyanide in healthy smokers and healthy 
non-smokers showed: in smokers the excretion of B 1 2 and 
SCN" in urine is increased. A high excretion of thiocyanate 
in urine is also related to an increase of the B 1 2 excretion 
and to a relatively low B 1 2 concentration in serum. The 
authors assume that the increased excretion does not suffice 
to explain the decreased B 1 2 concentration in serum. This 
may be rather the result of the disturbed equilibrium bet­
ween serum and tissue B 1 2 , caused by the high plasma 
cyanide concentration. 
Philips et al. (1968) tested aqueous humour of 16 patients, 
which was collected during cateract operation for the cont­
ent of vitamin B 1 2 microbiologically. Aqueous humour con­
tains an average of 30 pg/ml and thus corresponds in the 
order of magnitude to the cerebrospinal fluid. There are 
obvious differences between smokers and non-smokers. The 
vitamin B 1 2 content of aqueous humour in non-smokers is 
34.3 pg/ml, in smokers i t is only 20.2 pg/ml as mean value 
(p < 0.1). 
Cyanide seems to play a special part in the modification of 
vitamin B 1 2 metabolism. Dai ly injections of 0.7 ml of a 
0 . 1 % K C N solution in rats for 6 days decreases the B 1 2 
reserve of the liver on an average by 20°/o (Braekkan et al" 
1957). 
4, Clinical states and their pathogenesis following 
uptake of higher amounts of cyanide 
Occurrence of intoxication symptoms depends upon the 
velocity of the increase of cyanide in tissues. This decisive 
factor is determined by the kind of the cyanide compound, 
by the way of intoxication, by the ingested dose, and by the 
ability of the organism to detoxicate cyanide. Upon uptake 
of higher doses death can occur within a few minutes, upon 
medium doses survival times up to 3 h were observed. Small 
non-lethal doses may cause headache, vertigo, and irri tation 
of the mucous membranes of the eyes and throat. A n injec­
tion of cyanide into the A . carotis communis causes a hyper­
ventilation by excitation of the chemoreceptors of the glomus 
caroticum, as Heymans could show in 1931. 
The highly acute form of cyanide intoxication is characteriz­
ed by an apoplexy-like course. In most cases, the intoxicated 
person collapses wi th a short scream; dyspnea progressing to 
apnea, convulsion collapse and loss of consciousness follow. 
Death occurs within 1—2 min. 
The most frequently occurring form of intoxication is 
mainly determined by the central hypoxemic symptoms: 
hyperpnea, unconsciousness, generalized convulsions, and 
finally paralysis wi th complete areflexia. I n this case agony 
lasts 15—60 min . The actual cause of death in the acute 
intoxication is the cessation of respiration, which wi l l take 
place some minutes before cardiac arrest (Friedberg and 
Grü tzmacher 1968). 
4.1. Clinical states and their pathogenesis following 
uptake of cyanide for a long period of time 
The chronic uptake of cyanide in small doses, which as 
single doses do not cause clinical symptoms, is assumed to be 
decisive for the pathogenesis of a few diseases. A n inhibition 
of some ways of cyanide metabolism are probably respon­
sible in some cases (Schievelbein, Werle et al. 1969; Baumei­
ster 1972). As a result of a chronic cyanide intoxication the 
following clinical states have been described up to now: 
tobacco amblyopia, retrobulbar neuritis wi th pernicious 
anaemia, optic atrophy of Leber, Nigerian nutrit ional ataxic 
neuropathy, sterility in women who are heavy smokers. 
4.2. Tobacco amblyopia4) 
For the frequency of the tobacco amblyopia different 
values have been published by different authors. According 
to Hollwich et al. (1968) 1000 cases have been described in 
the total wor ld literature. I n contrast, according to Traquair 
(1930) in the years 1913—1929 only, 1525 cases were 
registered in two clinics in Edinburgh. 
The clinical state which only occurs in smokers, includes as 
the main symptom a central scotoma. Heaton et al. (1958) 
demand 7 criterions for the diagnosis (for details see H o l l ­
wich et al. 1968). I n patients wi th tobacco amblyopia vascu­
lar changes and degeneration of ganglion cells in the retina 
and of nerve fibres of the nervus opticus were described. 
Mainly involved are fibres which connect wi th the macular 
bundle (Duke-Elder 1954). 
Victor, Mancall , and Dreyfus (1960) published one case 
with centrocecal scotoma of both eyes upon alcohol and 
tobacco abuse. They described a degeneration of the papul-
omacular bundle up to the corpus geniculatum laterale w i th 
atrophy of the medullary sheaths and axis cylinder as well 
as fibrous gliosis. 
These pathological anatomic findings show a striking parallel 
to the observations in animal experiments on cyanide ad­
ministration. Repeated small doses of cyanide cause a 
demyelinization in the central nervous system in 
rats and monkeys (Hurst 1942; Lumsden 1950). Leishman 
(1951) thought to have observed a correlation between 
amblyopia and deficiency of gastric acid and therefore 
assumed a connection in the etiology of amblyopia and 
pernicious anaemia. 
The good therapeutic effect of v i tamin B 1 2 in the tobacco 
amblyopia suggests also deficiency of vi tamin B 1 2 as a cause. 
This can develop by a general malnutr i t ion wi th decreased 
uptake of vitamin B 1 2 , which is thought by several American 
authors (Victor 1963; K n o x 1970) to be a primary cause. 
This vitamin B 1 2 deficiency can also develop by a transfor­
mation of "functional" hydroxocobalamine into "non­
functional" cyanocobalamine. Experimental investigations 
support this hypothesis. 
Injection of sublethal doses in rats causes a significant 
decrease of the vi tamin B 1 2 store in the liver. These reserves 
are obviously an important factor i n detoxication of cyanide 
and therefore wi th high probability are hydroxocobalamine 
(Braekkan et al. 1957). Nut r i t iona l deficiency of vi tamin B 1 2 
causes an increased excretion of SCN". F rom this i t is con­
cluded that hydroxocobalamine and thiosulphate-sulphur-
transferase compete for the cyanide to be detoxicated (Wokes 
and Picard 1955b). These and similar results were the cause 
for investigations on the metabolism of vi tamin B 1 2 i n 
patients wi th tobacco amblyopia. I n 13 patients wi th tobacco 
amblyopia a mean value of 218 pg B 1 2 / m l serum was found, 
whereas the concentration in 12 healthy persons was on an 
average of 538 pg/ml (Heaton et al. 1958). I n this case the 
method of M o l l i n and Ross (1952, 1954) wi th Euglena 
gracilis as test organism was used. The position of cyanoco­
balamine in the total B 1 2 was significantly higher in patients 
wi th tobacco amblyopia compared wi th healthy persons 
(Wilson et al. 1971). 
4 ) Some authors do not differentiate between tobacco and alco­
hol amblyopia, but use the name tobacco-alcohol amblyopia. 
According to Harrington (1962) the amblyopia caused by 
alcohol can be differentiated from the tobacco amblyopia by 
exact quantitative perimetric analysis of the scotomas. The 
findings in tobacco amblyopia include central scotoma with 
infinite transitions, with the greatest density found in the 
field between the blind spot and the fixation point. This leads 
to difficulties in focusing and fixation. In the methyl alcohol 
amblyopia Harrington describes dense irregular, central 
scotomas with extreme loss of sight. 
Arzneim.-Forsch. (Drug Res.) 25, Nr. 7 (1975) 
Baumeister et al . - Cyanide 1059 
For a few years several authors have examined the meta­
bolism of this vitamin wi th radioactive-labelled vitamin 
according to the method described by Schilling (1953). 
Kommerel l and Castrillon-Oberndorfer (1968) found a 
severe alteration of B,.. absorption in 2 out of 5 patients with 
tabacco amblyopia. 
On the other hand, Watson et al. (1969) did not find a 
decrease of the absorption in 15 patients with tobacco 
amblyopia. But i f the patients smoked during the experi­
ment, the absorption of B 1 2 decreased. 
According to investigations of Foulds et al. (1968), 40% 
of patients wi th tobacco amblyopia showed decreased levels 
of serum B 1 2 . I n 45% the absorption of vitamin B 1 2 was 
disturbed. 
Foulds and coworkers (1969) could demonstrate in patients 
wi th tobacco amblyopia a direct correlation between the 
consumption of tobacco, the vitamin B 1 2 absorption, and 
the B 1 2 level in serum. I f amblyopia occurred in a patient 
wi th a small tobacco consumption the absorption of vitamin 
B 1 2 was insufficient, or the serum B 1 2 level was low. I f , 
however, the serum levels were high, the disease became 
manifest only upon extreme tobacco consumption. 
Foulds and coworkers (1968) also investigated the concen­
tration of serum thiocyanate in heavy smokers wi th tobacco 
amblyopia and in smokers without tobacco amblyopia, as 
well as in non-smokers. They found as already Stoa (1957) 
did, a significantly increased thiocyanate level in serum of 
smokers compared with the values in non-smokers. I n con­
trast to these findings the thiocyanate concentration in pa­
tients wi th tobacco amblyopia was significantly decreased 
compared wi th healthy smokers. Although the patients wi th 
tobacco amblyopia did smoke more than the healthy 
smokers. These findings suggest a possible enzyme defect, 
a hereditary deficiency of enzymes which are able to form 
SCN". 
Surveying the discussed results, approximately the following 
preliminary pathogenetic mechanism of the tobacco amblyo­
pia may be suggested: 
The patients take up higher amounts of cyanide wi th the 
tobacco smoke. 
The detoxication of cyanide is disturbed by 
a) a deficiency of available hydroxocobalaminc, 
by an insufficient nutritional administration, 
by a disturbed absorption, 
by an increased transformation into cyanocobalamine; 
b) by a hereditary deficiency of enzymes which are able 
to form SCN". 
The insufficiently detoxicated cyanide takes part in the 
impairment of the central nervous system. 
4.3. Retrobulbar neuritis in pernicious anaemia 
Besides the tobacco amblyopia, which is known to be 
frequently combined with pernicious anaemia, also a retro­
bulbar neuritis is described in pernicious anaemia, a seldom, 
but wel l known complication, which also may precede 
Biermer's anaemia (Cohen 1936). On the other hand, Free­
man (1961) stated: "We have presented evidence that tobacco 
amblyopia and retrobulbar neuritis in pernicious anaemia 
are one and the same condition". 
The histological findings at the nervus opticus (Bickel 1914) 
in the retrobulbar neuritis proved to be similar to those 
which are found in tobacco amblyopia (Duke-Elder 1954). 
Since up to now only one investigation has been published 
concerning the pathological anatomic findings in the retro­
bulbar neuritis in connection wi th pernicious anaemia, con­
firmation is still pending (Freeman 1961). 
4.4. Leber's optic atrophy 
This disease was described in 1871 by Leber as a hereditary 
one, in which an acute or subacute decrease of sight occurs 
together w i th the development of bilateral central scotomas. 
Leber's optic atrophy is found mostly in young men of 
about 20 years, though the age distribution varies in a wide 
range. 15% of the patients are women. In some patients 
diffuse encephalo-myelopathic complications occur either 
simultaneously wi th the decrease of sight or later (Innamura 
and Ichikawa 1919; Ferguson and Gritchky 1928; Colen-
brander 1951; Enghoff 1963; Wilson 1963; Lees et al. 1964). 
But the manifestations of the disease are extended to the 
central nervous system and to the eyes. Considering the 
hereditary nature of this disease and the clinical symptoms 
Wilson (1965a) concluded that the disease is caused by an 
enzymatic impairment, the manifestations of which are 
triggered by exogenous factors, at least the danger for the 
visual apparatus. 
The question of an enzymatic impairment could not be 
answered clearly by measuring the activity of the thiosul-
phate-sulphurtransferase. 
In liver tissue from needle biopsy a decreased activity of 
thiosulphate-sulphurtransferase was found for this patient 
compared wi th a control person. The liver of this patient 
showed at the post mortem examination a somewhat smaller 
enzymatic activity compared wi th 2 control livers. The 
enzyme content of a brain sample was, however, somewhat 
higher in the patient wi th Leber's optic atrophy compared 
with a control person. 
Wilson suggested smoking as an exogeneous factor for the 
manifestation of the visual disorder. I n healthy smokers the 
blood level and the excretion in urine of thiocyanate is 
increased compared wi th non-smokers, as mentioned above. 
In smokers with Leber's optic atrophy the increase of the 
thiocyanate level in blood is less pronounced or even absent. 
Patients wi th Leber's optic atrophy, smokers as well as non-
smokers, show a significantly higher portion of cyanacobal-
amine in the total B 1 2 content in serum compared with 
healthy persons. The ratio of methylcobalamineto coenzyme 
B 1 2 plus hydroxocobalamine is clearly decreased in Leber's 
optic atrophy (Wilson et al. 1971). The few adult patients 
with Leber's optic atrophy included, according to the ob­
servation of Wilson, 4 female and 2 male patients in whom 
the incidence of the symptoms was preceded by an acute 
pyelonephritis, in 2 children from families with Leber's 
optic atrophy the impairment of vision occurred in connec­
tion wi th an infection of the urinary tract (Wilson 1967). 
Adams et al. (1966) got experimental clues that the infection 
of the urinary tract wi th Ps. pyoceaneus and E. coli may 
contribute to the development of Leber's optic atrophy by 
formation of cyanide. Smith decribed already in 1964 infec­
tions as a source for cyanide. This could explain the rare 
cases in which also non-smokers are affected by this disease. 
4.5. Nigerian nutritional neuropathy 
The fully developed ataxic symptom of this disease, which 
occurs in Nigeria, exists of an atrophy of the nervus opticus, 
deafness and sensory spinal ataxia (Money 1958). The 
tropical amblyopia, probably a fragment form of the fully 
developed syndrome, was primarily explored in Nigeria by 
Moore (1930). Together with the tropic amblyopia and the 
ataxic syndrome, the literature also contains data on the 
occurrence of angular stomatitis, glossitis, and a dermatitis 
of the scrotum (for l i t . see Osuntokun et al. 1969). 
On account of these symptoms several authors supposed 
that this disease could be caused by a deficiency of vitamin 
B 1 2 . The frequent occurrence of the combined symptoms in 
the Nigerian population, which takes up a plant containing 
cyanide, namely Cassava (s. Table 1), as a main food source, 
led Clark (1935) to the supposition that the visual impair­
ment in tropical amblyopia is caused by a cyanide intoxica­
tion as a result of a great consumption of Cassava. 
Cassava contains linimarine, a cyanogenic glycoside. Fur­
thermore, the plant contains a hydrolase (linase) which 
quickly liberates considerable amounts of cyanide i f the 
leaves, the stem, or the starch containing roots are damaged. 
One Cassava species (Manioc utilissima), which is used in 
Nigeria most, has specially high concentrations of cyano-
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genie material in the outer layers of the tuberous root. F rom 
mere free cyanide gets into the inner part of the plant and 
thus can intoxicate me eatable parts (Osuntokun et al. 1968). 
A t a comparison between the concentration of thiocyanate 
and the level of vitamin B 1 2 in plasma of Nigerian patients 
who suffered from degenerative neurologic symptoms, and 
in plasma of healthy persons, the suggestion was confirmed 
that the patients had been confronted wi th a considerably 
high cyanide uptake. The thiocyanate concentration was 
highly significant in the patients. Also increased SCN" 
supply could be causative tor this increased SCN" concen­
tration. As a source for SCN" mainly mi lk and cruciferae 
may be considered. Consumption of both is almost zero in 
Nigeria. Therefore, as a main source only the Cassava plant 
is left. 
On determination of the total vi tamin B 1 2 content, no dif­
ferences were found between patients and healthy persons. 
However, the plasma content of hydroxocobalamine is smal­
ler in patients than in healthy persons (Monekosso and 
Wilson 1966). 
A comparison of the frequency of this disease in two Nige­
rian villages with institutional habits also shows that the 
uptake of Cassava plays a causative role in the degenerative 
neuropathia. I n the village wi th the higher Cassava consump­
tion the disease occurs wi th relatively high percentage. I n 
the patients increased plasma levels of thiocyanate are found 
(Osuntokun et al. 1969). 
A diminution or a complete absence of the sulphur-contain­
ing amino acids cysteine and methionine in plasma is also 
observed in this disease. I t seems to be possible that the 
detoxication of cyanide via formation of 2-amino-4-thiazoli-
dine-carboxylic acid is prevented because of the lack of 
cysteine (Osuntokun et al. 1968). 
4.6. Sterility in female heavy smokers 
According to a report of Heller, the rhodan content of the 
cervix mucus is between 0.2 and 1.0 mg/100 ml . The highest 
values are measured during the secretion phase. I n 7 women 
with sterility which could not be clarified, rhodan concen­
trations were found between 1.0 and 2.3 mg/100 ml . I n two 
heavy smokers values above 5 mg/100 ml were measured. 
I t seems to be certain that values above 1.0 mg can damage 
the spermatozoa. The sterility of female heavy smokers, 
which can frequently be observed, according to Heller 
(1960) could be explained in this way. Bettochi and Marcell i 
(1963), however, could not find an influence of smoking 
on the fertility of women. 
5. Treatment of cyanide intoxication 
5.1. Treatment of acute cyanide intoxication 
The therapeutic aim is the lowering of the cyanide concen­
tration in blood and tissue. This can be reached by specific 
and unspeciflc detoxication measures. A combination of 
both seems to be the optimal solution. 
5.2. Unspecific measures 
The elimination of H C N can be accelerated by forcing 
respiration. I f the respiration is intensified in HCN-free air, 
the partial pressure for H C N decreases in the alveoli. The 
concentration gradient to the blood plasma is increased so 
that the highly volatile gas, which is dissolved in plasma, 
can be eliminated. Artificial respiration, therefore, is recom-
mendable. Friedberg and Schwarzkopf (1969) found during 
spontaneous respiration only a small elimination of H C N 
via the lung. I t amounted to 1 to 2% of the infused dose. 
Artif icial respiration, however, increased the elimination of 
CN" 3—4fold. Also in animal experiments, Friedberg and 
Grü tzmacher (1968) observed that solely by a stimulation 
of respiration the intoxication can be lessened. 
Sheehy and Way (1968) found, in survival experiments in 
rats, after administration of cyanide that oxygen solely or 
combined with thiosulphate and sodium nitrite has a higher 
effectiveness than thiosulphate given alone. I n these experi­
ments an L D 5 0 of 31.5 mg/kg potassium cyanide was deter­
mined if 0.5g Na 2 S 2 0 3 /kg was given as antidote together 
with normal air. The L D 5 0 was increased to 63.8 mg/kg 
potassium cyanide, i f 100% pure oxygen was given. 
The adminstration of oxygen is based on the idea that an 
eventual arterial hypoxia, caused by an early paralysis of 
the respiratory centre, can be compensated in this way. 
Moeschlin recommends a high-pressure oxygen respiration 
in addition. According to Friedberg and Grü tzmacher (1968) 
the so-called cyanide resistant respiration could be of greater 
importance under the influence of an increased oxygen 
pressure. 
5.3. Specific measures 
Table 3 summarizes the specific measures applied in an 
acute cyanide intoxication. 
Sodium thiosulphate has a very high detoxication capacity 
(Lang 1895). A decisive handicap, however, is the relatively 
slow rate of action. Only after several minutes a therapeutic 
effect is seen (Friedberg 1968). I n very severe cases of 
intoxication wi th pending respiratory arrest the onset of 
detoxication of thiosulphate is too slow. 
A combined administration of sodium thiosulphate w i t h the 
detoxicating enzyme thiosulphate-sulphurtransferase was 
described by Clemedson et al. (1954). 
Producers of methemoglobin, primary nitrites (sodium 
nitrite for injection, amyl-nitrite for inhalation), have been 
used for 40 years in the treatment of cyanide intoxication 
(Hug 1932; Geiger 1933; Chen et al. 1933 a, b,). Methemo­
globin (ferric hemoglobin) transforms cyan-methemoglobin 
wi th cyanide binding the cyanide residue to the trivalent 
iron of the oxidized hemoglobin. A t a total hemoglobin 
amount of an adult person of about 1000 g and at a forma­
tion of hemoglobin of 10°/o, that is 100 g methemoglobin, 
theoretically 156 mg C N " can be bound. This approximately 
corresponds to the lethal dose (Friedberg 1968). 
According to Chen and Rose (1952) the combination of 
nitrites with thiosulphate has proved therapeutically suc­
cessful in animal experiments and in cases of intoxication. 
A new development in the field of methemoglobin producers 
are aminophenols, which have been recommended since 
1965 by Kiese and Weger (1965 a, b) for the detoxication 
of cyanide. 4-Dimethylaminophenol, so-called "new anti­
dote", exerts the quickest action in human blood compared 
Table 3: Specific therapeutic measures in acute cyanide intoxication in men. 
Substance Dose on i.v. injection Mechanism of action Literature 
Sodium thiosulphate 1-5 g Sulphur donator Klimmer (1971) 
12—25 g 
Sodium nitrite*; 300 mg Producer of methemoglobin Moeschlin (1964) 
4-Dimethylaminophenol 2.5—3.25 mg/kg Producer of methemoglobin Weger (1968), 
Klimmer (1971) 
Cobalt histidine 20 mg/kg Cyanide binding Klimmer (1971) 
Cobalt ethylenamine-tetraacetic acid 300—600 mg Cyanide binding Moeschlin (1964) 
(cobalt EDTA) 
Hydroxocobolamine 5—15 g Cyanide binding Friedberg (1968) 
*) Should not be used. 
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with other tested aminophenols. A methemoglobin concen­
tration of 15°/o was already reached in less than 1 min 
(Weger 1968, 1969; Kiese and Weger 1969). The optimum 
concentration of methemoglobin for the treatment of a 
cyanide intoxication is about 50% (Lörcher and Weger 
1971). 
Also with respect to its action on respiration and circulation, 
4-dimethylaminophenol is superior to nitrite and to the 
cobalt compounds: cobalt-histidine, cobalt-EDTA and to 
hydroxocobalamine. A model intoxication in cats wi th 8 mg 
K C N / k g showed that on treatment wi th hydroxocobalamine 
2 out of 3 animals died, on treatment wi th cobalt-EDTA 3 
out of 4. On treatment wi th NaNO* 7 out of 8 animals died 
whereas only 1 out of 8 animals died on treatment with 
4-dimethylaminophenol-HCl (Weger 1969). 
I n men 30% hemoglobin could be oxidized wi th doses of 
4-dimethylaminophenol, which had only little effect on blood 
pressure and pulse. Doses of sodium nitrate, which are 
recommended for therapy and which have a comparable 
effect, produced collapse. The formation of methemoglobin 
only reached a maximum concentration of 6% within 30 
min (Weger 1969; Kiese et al. 1968). Instead of methemo­
globin producers some authors recommend the application 
of cobalt compounds: hydroxocobalamine (Mushett et al. 
1952), cobalt-EDTA, and cobalt-histidine (Paulet 1957). 
These compounds have the advantage of reacting already 
within the plasma with the cyanide forming complexes with 
it (Friedberg 1968). 
The application of these cobalt compounds, however, seems 
to be dangerous; for, without proceeding HCN-application 
they cause a diminution of respiratory rate and a decrease 
of the blood flow of the A . carotis according to Weger 
(1969). These effects are brought about by cobalt-EDTA 
and cobalt-histidine to a higher degree than by hydroxo­
cobalamine. Therapeutically necessary doses of cobalt-
E D T A are lethal in experimental animals within 40 min 
(Weger 1969; Offterdinger and Weger 1969). 
I n a comparison of the velocity of action and the detoxi-
cation capacity of 4-dimethylaminophenol and cobalt-histi­
dine using the HCN-exhalation as a measure, 4-dimethyl­
aminophenol shows the same velocity of action as cobalt-
histidine but a considerably longer duration of action 
(Schwarzkopf and Friedberg 1970). Schwarzkopf and Fried-
berg, however, point to the additional risk for a patient 
intoxicated with cyanide by the increased methemoglobin 
content of the blood which is caused by application of 4-
dimethylaminophenol. 
5.4. Treatment of chronic cyanide intoxication 
I n diseases which are caused by chronic application of 
cyanide, the further application of H C N must be stopped 
as a primary measure. Currently, the medical treatment con­
sists of application of high doses of hydroxocobalamine. 
I n 1958 Wokes recommended the application of vitamin B 1 2 
p.o. in frequent small doses in consideration of the etiology 
of the tobacco amblyopia. 
The action of hydroxocobalamine and cyanocobalamine has 
been investigated experimentally and clinically in recent 
times. 
The premedication of mice wi th 50 mg/kg hydroxocobal­
amine prevents the toxic symptoms and the death of the 
animal which are caused by i.p. application of 5.5—8.0 
mg/kg potassium cyanide. Cyanocobalamine does not show 
this protective effect. I f the animals already showed respirat­
ory arrest and unconsciousness caused by cyanide intoxicat­
ion, most of the animals recovered quickly after the appli­
cation of hydroxocobalamine. I f the mice are given potas­
sium cyanide by hydroxocobalamine, part of the cyanide 
appears in the urine as SCN" (3.5%), as free cyanide 
(0.7%), and as cyanocobalamine (9.6%) within 2.5 h 
(Mushett et al. 1952). 
I f the rats are given K C N as s.c. injections up to 4 mg daily 
for 3 weeks, the treatment wi th hydroxocobalamine proved 
to be obviously superior to cyanocobalamine. The excretion 
of SCN" in urine increased in the experimental animals. The 
highest increase was observed in the group treated wi th 
hydroxocobalamine. The histological examination of the 
central nervous system revealed a demyelination in the 
untreated animals. The simultaneous administration of 
hydroxocobalamine protected the animals against these 
changes. The administration of cyanocobalamine, however, 
did not have this effect. The authors of this investigation 
(Smith and Duckett 1965) suppose that this extraordinary 
effect is caused by a mechanism of action which surpasses 
the merely chemical reaction between cyanide and hydroxo­
cobalamine. The authors discuss a general protective func­
tion of vitamin B 1 2 for the myelin. 
Most of the cases of tobacco amblyopia improve i f the 
patients stop smoking, but often this measure is not suffici­
ent (Griffi th 1897). I n smokers who continued smoking 
without reduction of the amount, the amblyopia got better 
much more quickly i f treated wi th cyanocobalamine com­
pared wi th a sole abstinence of smoking. Heaton et al. (1958) 
administered 100 mg of cyanocobalamine parenterally two 
times weekly for one month, another two months only once 
every two weeks, and finally the same dose once every 
month. I f there are no more clinical symptoms, the authors 
recommend discontinuing the treatment after 6 months. As 
commercial preparations of cyanocobalamine contain small 
amounts of hydroxocobalamine, the latter substance may 
be the substance actually effective in the therapeutic experi­
ments wi th "cyanocobalamine" (Smith and Duckett 1965). 
Chisholm et al. (1967) divided patients wi th tobacco ambly­
opia into two therapeutic groups. One was treated wi th i .m. 
injections of hydroxocobalamine, the other wi th cyanocobal­
amine. The improvement of visual acuity in the group 
treated wi th hydroxocobalamine was significantly higher 
compared wi th the group treated wi th cyanocobalamine. 
Also the chromatic vision was improved to a higher degree 
under treatment wi th hydroxocobalamine compared wi th 
cyanocobalamine. I n patients who did not stop smoking, 
total healing could not be achieved in a single case wi th 
cyanocobalamine medication, but healing could be achieved 
with hydroxocobalamine. 
Bronte-Stewart et al. (1968) report on the treatment of a 
patient wi th metabolic encephalopathy, tobacco amblyopia, 
and a lung abseess. The encephalopathy responded to the 
treatment wi th cyanocobalamine, the tobacco amblyopia, 
however, did not improve unti l hydroxocobalamine was ad­
ministered. 
These clinical improvements are paralleled by biochemical 
changes in the body of the patient. Chisholm and Pettigrew 
(1970) could show that the plasma thiocyanate concentration 
of their patients increased significantly and reached the 
values of healthy smokers after treatment wi th hydroxocobal­
amine for 6 months. Also, the thiocyanate excretion in urine 
was increased. 
According to Kommereil and Castrillon-Oberndorfer (1968) 
the following schedule of treatment for the tobacco amblyopia 
seems to be substantiated (corresponding to the schedule for 
patients with pernicious anaemia according to Glass 1964; 
Heinrich 1964; Waller and Castrillon-Oberndorfer 1968): 
Every two days 1 ampule of hydroxocobalamine at 500 mg 
i.m., 22 injections. Maintenance therapy wi th 1 ampule at 
500 mg hydroxocobalamine once a month. Under this 
therapy the sight can be improved essentially, even i f no 
abstinence of tobacco and alcohol can be achieved. 
For treatment of Leber's optic atrophy Adams et al. (1966) 
recommended the administration of massive doses of 
hydroxocobalamine besides the strict prohibition of smoking 
and the intense treatment of an eventual infection as cyanide 
source. Chisholm and Pettigrew (1970) found, after treat­
ment of these patients wi th hydroxocobalamine for 12 
months, an increase of the plasma thiocyanate concentration 
and an increase of the thiocyanate excretion in urine. This 
corresponds to the results of the treatment of the tobacco 
amblyopia. The improvement of sight, however, was only 
slight in these cases. 
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